Abstract The 2026 proposal to stage type 2 diabetes by β-cell trajectory and continuous glucose monitoring (CGM) metrics—specifically time in tight range (TITR)—represents a pivotal advance in dysglycaemia phenotyping. Yet, this innovation exposes a critical translational void: actionable algorithms to convert granular CGM outputs into stage-specific, stability-oriented therapeutic responses remain absent from clinical guidelines.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile